19 Sep 06
Strategic Research Institute‚Äôs Phase IV Clinical Trials (PCT) conference features a fully packed informational two day event organized into a series of discussions focusing on the major Phase IV and Patient Recruitment/ Retention issues of today.
19 Sep 06
GAIN VALUABLE INSIGHT INTO:
‚ÄĘ How CMS‚Äô movement toward P4P will Impact Healthcare and Payors Nationwide
‚ÄĘ Large Employer HR Strategy: How Aligning Incentives and Creating a Health
‚ÄĘ Information Exchange will Reduce your Healthcare Spend
‚ÄĘ Health Plans: How Data, Transparency and Consumers will Affect your P4P Initiatives
19 Sep 06
Five Presentations from CMS including an Update on the 2007 Landscape
Understanding the Short- and Long-Term Impact of Part D
Strategies for Driving Senior Enrollment
Innovative Approaches to Public & Private Partnerships
Analyzing Patient Perceptions of Out-of-Pocket Costs
The Importance of Pharmacoeconomic Data
Securing Favorable Formulary Coverage in the Part D Environment
The Future of Employer Plans
30 Aug 06
In an earlier field report, we looked at some of the issues surrounding manufacturing process instructions (MPIs) and manufacturing process records (MPRs). I want to look at the issue of recording data in MPRs in more detail, as the format of your MPR has a huge impact on its usability and therefore the error rate.
PharmiWeb.com Field Reporter: Jo Hills
23 Aug 06
Paul Hawkins, the General Secretary for the Health and Beauty Association, tells us his philosophy for career progression and how the H&BA‚Äôs new website will help them to progress. The website itself promotes HBA‚Äôs attempt to bring Health and Beauty companies together in debating and discussing how to develop and adapt the industry to meet changing customer and consumer needs. Paul hopes the move towards e-business will do just that.
22 Aug 06
You may not exactly be breaking into the gold vaults at Fort Knox, scaling the heights of MI5 √† la James Bond or hacking into The Pentagon security system, but you want to enter the pharmaceutical industry, which can be nearly as difficult.
08 Aug 06
Andy Sarfas is our mover and shaker of the week. He is the Global Internet Business Manager for Reckitt Benckiser.
08 Aug 06
David Mitchell is the Commercial Director at McNeil Consumer Healthcare, a company that produces remedies for self-treatment available at pharmacies and supermarket stores.
08 Aug 06
Alex Bishop is the IT Business Manager at Pfizer, the largest supplier of medicines to the NHS.
04 Aug 06
Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.
03 Aug 06
Manufacturing Instructions and Records: Operators are expected to follow manufacturing instructions to produce a product that meets the required specification. Typically these instructions will be written by technical experts, the chemical engineers who were responsible for the technology transfer, the process validation and so on.
PharmiWeb.com Field Reporter: Joanna Hills
02 Aug 06
Every sponsor or CRO can expect their country‚Äôs regulatory agency to arrive on their premises periodically to conduct routine inspections. In the UK, for instance, the Medicines and Healthcare products Regulatory Agency (MHRA) conducts routine periodic inspections approximately every three years. Apart from these, the MHRA also conducts ‚Äúfor cause‚ÄĚ and ‚Äúfollow up‚ÄĚ inspections, and they also take part in the third-country inspection program. Because all inspections may be either announced or unan
01 Aug 06
Dr Mark Ballard, the Medical Director of Respiratory and Dermatology Therapeutic Areas at the Novartis Pharmaceuticals Corporation answers our questions about their eczema cream Elidel.
01 Aug 06
Doctors taking part in a survey on Alzheimer‚Äôs Disease (AD) management have called for clear and consistent guidelines on diagnosis and treatment of the condition to be drawn up as a matter of urgency. The survey was sponsored by Eisai Europe Ltd and Pfizer Inc, who market the cholinesterase inhibitor Aricept (donepezil), and was presented during the International Conference on Alzheimer‚Äôs Disease and Related Disorders.
Olwen Glynn Owen ‚Äď Pharmiweb Field Reporter
31 Jul 06
The Treasury is aware of a growing trend, which has recently moved into the pharmaceutical sector, for staff to be provided to clients through ‚Äúumbrella‚ÄĚ or ‚Äúcomposite‚ÄĚ companies. These companies promise a golden scenario of reduced costs to their clients and greater take-home pay to the individuals who work through them.
25 Jul 06
Cognitive behaviour therapy (CBT) combines two very effective kinds of psychotherapy delivered face to face by medical therapists
Jim Melling - PharmiWeb Field Reporter
25 Jul 06
In the last report we analysed part of an SOP control system for inefficiencies and opportunities for error, by mapping the system and asking ‚Äėwhat if?‚Äô at each stage. But, as we mentioned previously, documentation systems (or, indeed, any type of control system) rarely operate in isolation. So let‚Äôs look at some of the inputs and outputs there might be on a typical site, using the same process as before.
Joanna Hills - PharmiWeb Field Reporter
21 Jul 06
PowderMed has submitted an application to UK regulators seeking to conduct human trials of its avian influenza vaccine. Developing an effective vaccine against the next influenza pandemic is a challenging task, but one many companies are taking on. However, until a virus able to cause a pandemic emerges, no one knows for certain which product will be most effective.
19 Jul 06
Hints and Tips: Survive in the Work Place Part Two
Elaine Ford - PharmiWeb Field Reporter
11 Jul 06
Baraclude (entecavir), a new oral drug developed by Bristol-Myers Squibb, recently approved by the European Commission for treatment of chronic hepatitis B viral (HBV) infections, is expected to become available in a few months in some countries of the EU, the Middle East and Africa.
Olwen Glynn Owen - PharmiWeb Field Reporter
11 Jul 06
The FDA has approved Tibotec and Johnson & Johnson's HIV drug Prezista, enabling it to join Boehringer Ingelheim's recently launched Aptivus as one of just two second-generation protease inhibitors currently available. However, competition will be fierce as both drugs target similar patients in a crowded market where small differences in marketing approaches could impact hugely on sales.
10 Jul 06
ROCHE is set to file for a new indication for its oral, targeted cancer drug Xeloda¬ģ following impressive new data presented at the American Society of Clinical Oncology conference (ASCO).
07 Jul 06
Todays Headlines from across the DailyUpdates network (July 7th, 2006) - In today's edition we highlight Biomarin's development of the novel antihypertensive 6R-BH4 and new research describing a promising molecular target for future sepsis therapeutics.
05 Jul 06
Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, ABIO 08/01. In addition we feature a review describing a potentially groundbreaking drug delivery technology. This technology harnesses protein transduction domains (PTDs), endogenous peptide sequences
27 Jun 06
Todays Headlines from across the DailyUpdates network - Today we feature news from Vasogen on their candidate treatment of chronic heart failure plus new data from Johnson & Johnson on a new integrin antagonist that may underly a future treatment of asthma
21 Jun 06
Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate